20 March 2015Americas

BMS sues Mylan to block Reyataz generic

Bristol-Myers Squibb (BMS) has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz (atazanavir sulphate).

BMS brought the action at the US District Court for the District of New Jersey on Tuesday (March 17).

Reyataz is an anti-retroviral drug that is combined with other HIV medications. In 2014, it generated worldwide sales of $1.3 billion.

BMS filed in the suit in response to Mylan’s filing of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration to market generic atazanavir sulphate tablets in three different strengths before the patent expires.

The patent, titled “Bisulphate salt of HIV protease inhibitor”, is due to expire in December 2018.

BMS has asked the court to find that the patent is valid and enforceable, has been infringed by Mylan’s ANDA submission and will be infringed by Mylan’s proposed generic product.

It also asked that any approval of Mylan’s ANDA be issued after the patent expires.

BMS has requested a permanent injunction to stop Mylan from making or selling its generic atazanavir sulphate tablets.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
12 September 2017   Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).

More on this story

Americas
12 September 2017   Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).

More on this story

Americas
12 September 2017   Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).